Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06140524
Title	A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma (LINKER-MGUS1)
Acronym	LINKER-MGUS1
Recruitment	Recruiting
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	Regeneron Pharmaceuticals
Indications	smoldering myeloma
Therapies	Linvoseltamab
Age Groups:	adult \| senior
Covered Countries	USA \| ESP

Filter rows:

Showing 1 to 11 of 11 entries

Facility	Status	City	State	Zip	Country	Details
Dana-Farber Cancer Institute	RECRUITING	Boston	Massachusetts	02215	United States	Details
Hospital Clinico Universitario Virgen De La Arrixaca	RECRUITING	El Palmar	Murcia	30120	Spain	Details
Hospital de Cabuenes	RECRUITING	Gijon	Asturias	33203	Spain	Details
Hospital General Universitario Morales Meseguer	RECRUITING	Murcia		30008	Spain	Details
Hospital Sant Pau	RECRUITING	Barcelona		08041	Spain	Details
Hospital Universitari Mutua Terrassa	RECRUITING	Terrassa	Barcelona	08221	Spain	Details
Hospital Universitario Virgen de las Nieves	RECRUITING	Granada	Andalusia	18014	Spain	Details
Johns Hopkins Hospital	RECRUITING	Baltimore	Maryland	21287	United States	Details
Stony Brook University Hospital	RECRUITING	Stony Brook	New York	11794	United States	Details
Universitaru Hospital La Princesa	RECRUITING	Madrid		28006	Spain	Details
University of Washington	RECRUITING	Seattle	Washington	98109	United States	Details

Showing 1 to 11 of 11 entries

Filter rows:

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field